MSH|^~\&|LAB|RCH|||201911081450||ORU^R01|4103208|D|2.3|||AL|NE
PID|1||RC00007229|RC7037|LABTEST^ALMONDTHINS^||20130120|F||||||||||RC000622/19|9875495454
OBR|1|34521^LAB|00026529^2510:C00008R^LAB^251019:C8^34521|522.2490^BHCG^Beta-HCG^^^21198-7||201910250903|201910250700|||||||201910250903||||||||||LAB|F||||
NTE|1||OUTSIDE LINEARITY HIGH
OBX|1|ST|522.2510^BHCG R^Beta-HCG^^21198-7^21198-7|1|45139^^Y|IU/L|<10|H||A^S|F|||201911081450
NTE|1||Reference Intervals, (guideline only) FOR B-HCG (U/L):
NTE|2||
NTE|3||Male or non-pregnant female            Less than 10
NTE|4||Pregnant female:
NTE|5||Time after LMP:        Expected beta-HCG range(WHO 3rd IRP):
NTE|6||4th  week                               25 - 426
NTE|7||5th  week                               25 - 7340
NTE|8||6th  week                             1080 - 56500
NTE|9||10th week                            54100 - 288000
NTE|10||18th week                             8910 - 66000
NTE|11||31st week                             5310 - 27400
NTE|12||*************************NOTE*******************************
NTE|13||Occasional patients with heterophile antibodies may have
NTE|14||erroneous BHCG results. Serum BHCG should not be used for
NTE|15||routine pregnancy tests. Urine does not contain heterophile
NTE|16||antibodies and may be used where apparent discrepant results
NTE|17||are experienced.
NTE|18||Method:Beckman Access/DxI

MSH|^~\&|LAB|RCH|||201911081451||ORU^R01|4103209|D|2.3|||AL|NE
PID|1||RC00007325|RC7134|LABTEST^AIR^UPTEMPO||19740306|M||||||||||RC000949/18|9875474973
OBR|1|34519^LAB|00026527^2510:C00006R^LAB^251019:C6^34519|500.1000^CP7^Chem 7 - Glu R,Urea,Crea,Lytes^^^XXX-1710||201910250902|201910250700|||||||201910250901||||||||||LAB|I||||
NTE|1||Outside normal low
OBR|2|34519^LAB|00026527^2510:C00006R^LAB^251019:C6^34519|522.2490^BHCG^Beta-HCG^^^21198-7||201910250902|201910250700|||||||201910250901||||||||||LAB|F||||
NTE|1||Outside normal low
OBX|1|ST|522.2510^BHCG R^Beta-HCG^^21198-7^21198-7|1|3476^^Y|IU/L|<10|H||A^S|F|||201911081451
NTE|1||Method:Beckman Access/DxI

MSH|^~\&|LAB|RCH|||201911081451||ORU^R01|4103210|D|2.3|||AL|NE
PID|1||RC00006059|RC6052|LABTEST^ALASKA^ROLL||19900918|F||||||||||RC000620/19|9876521172
OBR|1|34518^LAB|00026526^2510:C00005R^LAB^251019:C5^34518|522.2490^BHCG^Beta-HCG^^^21198-7||201910250901|201910250700|||||||201910250900||||||||||LAB|F||||
NTE|1||Outside normal high
OBX|1|ST|522.2510^BHCG R^Beta-HCG^^21198-7^21198-7|1|3213^^Y|IU/L|<10|H||A^S|F|||201911081451
NTE|1||Reference Intervals, (guideline only) FOR B-HCG (U/L):
NTE|2||
NTE|3||Male or non-pregnant female            Less than 10
NTE|4||Pregnant female:
NTE|5||Time after LMP:        Expected beta-HCG range(WHO 3rd IRP):
NTE|6||4th  week                               25 - 426
NTE|7||5th  week                               25 - 7340
NTE|8||6th  week                             1080 - 56500
NTE|9||10th week                            54100 - 288000
NTE|10||18th week                             8910 - 66000
NTE|11||31st week                             5310 - 27400
NTE|12||*************************NOTE*******************************
NTE|13||Occasional patients with heterophile antibodies may have
NTE|14||erroneous BHCG results. Serum BHCG should not be used for
NTE|15||routine pregnancy tests. Urine does not contain heterophile
NTE|16||antibodies and may be used where apparent discrepant results
NTE|17||are experienced.
NTE|18||Method:Beckman Access/DxI